Showing results (441-450 of 569) with videos related to

Sort By:
Pageof 57
Cancer Investigation|January 1, 1995
Taxanes: a new class of antitumor agentsM T Huizing, V H Misser, R C Pieters, et al.
Biochimica Et Biophysica Acta|March 4, 2000
Differential effects of gemcitabine on ribonucleotide pools of twenty-one solid tumour and leukaemia cell linesC J van Moorsel, A M Bergman, G Veerman, et al.
Cancer Research|June 11, 1999
Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2J H Hooijberg, H J Broxterman, M Kool, et al.
Analytical Biochemistry|October 10, 1995
Quantification of 5-fluorouracil incorporation into RNA of human and murine tumors as measured with a sensitive gas chromatography-mass spectrometry assayG J Peters, P Noordhuis, A Komissarov, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 4, 2001
Rb, mcl-1 and p53 expression correlate with clinical outcome in patients with liver metastases from colorectal cancerH H Backus, J M van Riel, C J van Groeningen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 8, 2001
Expression of X-linked inhibitor of apoptosis as a novel prognostic marker in radically resected non-small cell lung cancer patientsC G Ferreira, P van der Valk, S W Span, et al.
Journal of Immunological Methods|January 11, 2001
Potent expansion of human natural killer T cells using alpha-galactosylceramide (KRN7000)-loaded monocyte-derived dendritic cells, cultured in the presence of IL-7 and IL-15van der Vliet HJ, N Nishi, Y Koezuka, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1994
Clinical and pharmacologic study of multidrug resistance reversal with vinblastine and bepridilS C Linn, C K van Kalken, O van Tellingen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1994
Leukemia risk following Hodgkin's disease: relation to cumulative dose of alkylating agents, treatment with teniposide combinations, number of episodes of chemotherapy, and bone marrow damageF E van Leeuwen, A M Chorus, A W van den Belt-Dusebout, et al.
Biotherapy (Dordrecht, Netherlands)|January 1, 1992
Treatment with tumour infiltrating lymphocytes and interleukin-2 in patients with metastatic melanoma: a pilot studyJ W Baars, J C Fonk, R J Scheper, et al.
Pageof 57